{"gene":"ABL2","run_date":"2026-06-09T22:02:37","timeline":{"discoveries":[{"year":2008,"finding":"ABL2/ARG directly binds plexin A1 (but not a cytoplasmic-domain-lacking plexin A1 mutant) downstream of SEMA3F/NRP2 receptor complex, then phosphorylates and activates p190RhoGAP, which inactivates RhoA (GTP→GDP), resulting in cytoskeletal collapse and inhibition of cell migration. Cells expressing an ABL2 kinase-dead mutant or treated with ABL2 siRNA failed to inactivate RhoA.","method":"Co-immunoprecipitation, siRNA knockdown, kinase-dead mutant overexpression, RhoA activity assay (GTP/GDP), in vitro phosphorylation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding assay with domain mutant, kinase-dead mutant, siRNA, and biochemical RhoA activity readout in a single focused study; independently supported by follow-up papers (PMID:24759231)","pmids":["18660502"],"is_preprint":false},{"year":2011,"finding":"Crystal structures of ABL2 kinase domain in complex with imatinib, VX-680 (tozasertib), and a type I triazole carbothioamide inhibitor were solved. Imatinib binds both the ATP-binding site of the inactive kinase and the regulatory myristate-binding site. VX-680-bound and type-I-inhibitor-bound structures reveal a DFG motif in a conformation intermediate between active and inactive states.","method":"X-ray crystallography (co-crystal structures)","journal":"Journal of medicinal chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — three independent co-crystal structures in one rigorous structural study","pmids":["21417343"],"is_preprint":false},{"year":2012,"finding":"Arg/Abl2 knockdown in breast cancer cells increases Ras-MAPK signaling and proliferation-associated gene expression while decreasing invasion-associated gene expression, demonstrating that Arg promotes tumor cell invasion/intravasation/metastasis in vivo while simultaneously suppressing tumor growth.","method":"shRNA knockdown in xenograft mouse model, gene expression analysis, in vivo invasion and intravasation assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo xenograft with multiple phenotypic readouts (proliferation, invasion, intravasation, metastasis) and pathway analysis; single lab","pmids":["22777352"],"is_preprint":false},{"year":2012,"finding":"Arg/Abl2 increases the stoichiometry of cortactin binding to F-actin at saturation, and the Arg C-terminal calponin homology (CH) domain is necessary and sufficient for this effect. Arg–cortactin protein–protein interactions are required for optimal cortactin–actin affinity.","method":"Actin co-sedimentation assays with Arg deletion mutants and fragments","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro reconstitution with defined deletion mutants, single lab, multiple constructs tested","pmids":["22849492"],"is_preprint":false},{"year":2013,"finding":"Arg knockdown in hippocampal neurons destabilizes dendrite arbors via a RhoA-dependent mechanism, and destabilizes dendritic spines via an NMDA receptor-dependent relocalization of cortactin from spines; forcing cortactin into spines via fusion to Arg's actin-binding region prevents spine loss, demonstrating two distinct cytoskeletal control pathways for spine vs. dendrite stability.","method":"shRNA knockdown in cultured hippocampal neurons, live imaging, RhoA inhibition, NMDA receptor block, cortactin–Arg actin-binding domain fusion rescue","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal genetic and pharmacological interventions with specific phenotypic rescue in a single rigorous study","pmids":["23365224"],"is_preprint":false},{"year":2013,"finding":"Eight full-length Arg/Abl2 isoforms are endogenously expressed in human cells; the 1BSCTS isoform has nuclear distribution and phosphorylates CrkII in the nucleus, while the other seven isoforms are cytoplasmic. Isoforms 1BLCTL, 1BSCTL, and 1ASCTS decrease stress fibers and increase p190RhoGAP phosphorylation, whereas other isoforms induce different morphological effects without reducing stress fibers.","method":"Isoform transfection in COS-7 cells, immunofluorescence localization, phospho-CrkII and phospho-p190RhoGAP western blotting","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — systematic isoform overexpression with multiple readouts; single lab","pmids":["23707396"],"is_preprint":false},{"year":2014,"finding":"Arg/Abl2 stabilizes actin filaments against depolymerization via its internal (I/L)WEQ actin-binding domain, stimulates Arp2/3-mediated actin branch formation (requiring the IWLEQ domain; autoinhibition by the CH domain revealed by ArgΔCH), and potentiates cofilin-mediated actin filament severing; cortactin cooperates with Arg to stabilize filaments and attenuates Arg-enhanced cofilin severing.","method":"In vitro TIRF microscopy actin assembly assays, actin depolymerization assays, branching assays with purified Arp2/3, cofilin severing assays; Arg domain deletion mutants","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple reconstituted in vitro assays with purified proteins and defined deletion mutants in a single rigorous study","pmids":["25540195"],"is_preprint":false},{"year":2015,"finding":"The Arg kinase domain directly binds a lysine-rich membrane-proximal segment of the integrin β1 cytoplasmic tail; Arg phosphorylates β1 tail Tyr-783; the Arg SH2 domain then engages this phospho-Tyr-783 region; these interactions mediate direct Arg–β1 integrin binding in vitro and in cells, and activate Arg kinase activity.","method":"In vitro pulldown/binding assays, site-directed mutagenesis, in vitro kinase assay, co-immunoprecipitation from cells, kinase activity measurement","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro binding reconstitution, mutagenesis, kinase activity assay, and cell-based co-IP; single lab with multiple orthogonal methods","pmids":["25694433"],"is_preprint":false},{"year":2015,"finding":"Crystal structure of mouse ARG/Abl2 catalytic domain in complex with dasatinib at 2.5 Å resolution; dasatinib-bound ARG adopts a DFG-in conformation despite being non-phosphorylated on the activation-loop tyrosine, with a relatively open P-loop conformation compared to other ABL family inhibitor complexes.","method":"X-ray crystallography (co-crystal structure at 2.5 Å)","journal":"Acta crystallographica. Section F, Structural biology communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — high-resolution co-crystal structure with structural analysis; single study","pmids":["25849507"],"is_preprint":false},{"year":2016,"finding":"Abl2 kinase phosphorylates MNRR1 (CHCHD2) at tyrosine-99 within mitochondria; this phosphorylation promotes MNRR1 binding to cytochrome c oxidase (COX) and stimulates respiration. A disease-associated Q112H MNRR1 mutation impairs interaction with Abl2, reduces tyrosine phosphorylation, and causes defective respiration.","method":"In vitro kinase assay, co-immunoprecipitation, subcellular fractionation, respiration measurement, disease mutant analysis","journal":"Biochimica et biophysica acta. Molecular cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical phosphorylation assay, co-IP, functional respiration readout, and disease-mutant validation; single lab","pmids":["27913209"],"is_preprint":false},{"year":2016,"finding":"Loss of Abl2/Arg kinase in vivo yields a subpopulation of high-release-probability, GluN2B-containing immature hippocampal synapses that persist into early adulthood; these synapses show elevated NMDA receptor currents and enlarged spine heads. As arg−/− mice age, these synapses increase in proportion coinciding with net synapse loss, and both LTP and LTD become significantly altered by P42.","method":"Arg knockout mice, focal glutamate uncaging, electrophysiology (mEPSC, LTP, LTD), immunostaining for GluN2B, morphological spine analysis","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with multiple orthogonal electrophysiological and morphological readouts in vivo; rigorous study","pmids":["27335408"],"is_preprint":false},{"year":2017,"finding":"Corticosterone exposure reduces Abl2/Arg protein levels and phosphorylation of its substrates p190RhoGAP and cortactin in hippocampal neurons, preceding dendrite arbor atrophy; pharmacological activation of Arg kinase with a small-molecule activator (DPH) corrects dendrite arbor simplification and corticosterone-induced behavioral deficits.","method":"Western blotting for Arg and substrate phosphorylation in cortisol-treated mice, pharmacological Arg kinase activation with DPH, dendritic morphology analysis, behavioral tests","journal":"Molecular and cellular neurosciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological activation rescue with specific phenotypic readouts, western blot for substrate phosphorylation; single lab","pmids":["29107098"],"is_preprint":false},{"year":2017,"finding":"ABL2 overexpression in FLT3-ITD-expressing Ba/F3 cells partially suppresses FLT3-ITD-induced proliferation and colony formation by blocking AKT phosphorylation without affecting ERK1/2 or p38, or altering FLT3 kinase activity, ubiquitination or stability. ABL2 was identified as a FLT3 interacting protein by SH2 domain array screen.","method":"SH2 domain array screen, co-immunoprecipitation, Ba/F3 cell overexpression, proliferation and colony formation assays, phospho-AKT/ERK/p38 western blotting","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — SH2 domain screen plus functional overexpression with multiple signaling readouts; single lab","pmids":["28086240"],"is_preprint":false},{"year":2018,"finding":"Abl2 localizes with cortactin at wave-like ventral actin structures at the lamellum-lamellipodium interface and at cortactin-positive foci co-localizing with integrin β3 and paxillin; the Abl2 C-terminal half (actin- and microtubule-binding domains, not the kinase domain) is necessary and sufficient for recruitment to these wave structures and for supporting normal lamellipodium size.","method":"TIRF microscopy live imaging, Abl2 knockout cells, domain complementation with N- and C-terminal Abl2 halves, immunofluorescence co-localization","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct live imaging with knockout rescue and domain analysis; single lab, multiple orthogonal approaches","pmids":["30256707"],"is_preprint":false},{"year":2019,"finding":"The TAZ transcriptional co-activator drives expression of ABL2 and AXL in lung adenocarcinoma cells; ABL2 in turn phosphorylates TAZ to promote its nuclear localization, establishing an autocrine AXL-ABL2-TAZ feed-forward loop required for brain metastasis colonization. Knockdown of ABL2 or pharmacological inhibition with a BBB-penetrant ABL allosteric inhibitor markedly decreases brain metastases.","method":"shRNA knockdown of ABL2/AXL/TAZ, in vivo brain metastasis mouse model, TAZ phosphorylation assay, pharmacological ABL allosteric inhibitor treatment, transcriptional reporter assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple knockdowns plus pharmacological intervention in in vivo model with mechanistic phosphorylation readout; single lab","pmids":["31825826"],"is_preprint":false},{"year":2019,"finding":"The 1ALCTL and 1BLCTL Arg/Abl2 isoforms differentially regulate fibroblast activation and ECM remodeling: 1BLCTL promotes proliferation, migration/invasion, and induces a tumor-supportive milieu, while 1ALCTL maintains active focal adhesions and cell adhesion. Both isoforms support myofibroblast features including ECM contraction and stiffness.","method":"Arg isoform rescue in Arg−/− MEFs, proliferation/migration/invasion assays, focal adhesion analysis, ECM contraction assays","journal":"Biology open","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — isoform-specific rescue experiments with multiple cellular readouts; single lab","pmids":["30837227"],"is_preprint":false},{"year":2020,"finding":"ABL2 tyrosine kinase is identified as an upstream regulator of HSF1 protein expression; the ABL2 SH3 domain directly interacts with HSF1 at a noncanonical, proline-independent SH3 interaction motif. Allosteric (but not ATP-competitive) ABL2 inhibitors disrupt this interaction and impair HSF1 protein expression and HSF1-E2F transcriptional gene targets required for brain metastasis survival.","method":"Co-immunoprecipitation, SH3 domain binding assay, pharmacological inhibitor comparison (allosteric vs ATP-competitive), shRNA knockdown, transcriptional target measurement","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein interaction with domain specificity, pharmacological dissection with two inhibitor classes, and functional transcriptional readout; single lab","pmids":["33318173"],"is_preprint":false},{"year":2020,"finding":"Abl2 acts as a regulator of endocytic vesicle maturation during HPV16 uptake; Abl2 inhibition causes accumulation of misshaped endocytic pits without reducing their number, whereas EGFR inhibition reduces pit number. Abl2 mediates downstream signaling of EGFR during HPV16 internalization, distinct from Src-mediated macropinocytosis.","method":"Pharmacological inhibition of Abl2 and EGFR, electron/fluorescence microscopy of endocytic pits, virus uptake quantification","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct morphological quantification of endocytic intermediates under Abl2 inhibition; single lab, two inhibitor classes compared","pmids":["32188731"],"is_preprint":false},{"year":2021,"finding":"Arg/Abl2 depletion in endothelial cells activates both RhoA and Rac1, increases cell spreading, redistributes integrin-dependent adhesions to the cell periphery, improves ECM adhesion, and reduces barrier disruption in response to inflammatory agents. In vivo, genetic Arg deletion diminishes vascular leak in skin and lungs. Arg is activated in endothelium during inflammation in murine lungs and septic patient microvessels.","method":"siRNA depletion, RhoA/Rac1 activity assays, transendothelial electrical resistance, in vivo vascular permeability assays, immunofluorescence of patient tissue","journal":"Angiogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO in vivo plus siRNA depletion with multiple mechanistic readouts (GTPase activity, adhesion, barrier); single lab","pmids":["33770321"],"is_preprint":false},{"year":2021,"finding":"Abl2 binding to cortactin tethers Abl2 in dendritic spines, where Abl2 and cortactin maintain a small pool of stable actin filaments required for spine stability. Disruption of Abl2:cortactin interactions by FRAP of GFP-actin eliminates the stable actin pool in spines and significantly reduces spine density. Tonic synaptic activity rescues spine loss after Abl2 depletion by promoting cortactin enrichment in spines.","method":"FRAP of GFP-actin in cultured hippocampal neurons, shRNA knockdown of Abl2, Abl2:cortactin interaction mutants, pharmacological synaptic activity manipulation","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — FRAP with multiple genetic and pharmacological manipulations, rescue experiments, and direct stable actin pool quantification; replicated mechanistic findings across related Koleske lab papers","pmids":["33622779"],"is_preprint":false},{"year":2021,"finding":"Abl2 SH2 domain directly binds phosphotyrosine Y771 in the PDGFRβ cytoplasmic domain; PDGFRβ directly phosphorylates novel sites on Abl2 including Y116, Y139, Y161 (SH3 domain), Y299, Y303, Y310 (kinase domain); Y116, Y161, Y272, and Y310 are at/near the SH3/SH2-kinase linker interface. PDGFRβ-mediated phosphorylation activates Abl2 kinase activity, and mutation of Y116/Y161/Y272/Y310 to Phe abrogates this activation.","method":"In vitro direct binding assay, in vitro kinase assay with mass spectrometry phosphosite mapping, site-directed mutagenesis (4xF mutant), Abl2 kinase activity measurement","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of receptor-kinase interaction and phosphorylation, MS-mapped sites, mutagenesis abolishing activation; single lab with multiple orthogonal methods","pmids":["34144039"],"is_preprint":false},{"year":2022,"finding":"TGFβ1/Smad signaling and reactive oxygen species production increase ubiquitination and degradation of Abl2 protein in ccRCC cells; Abl2 promotes TGFβ1-induced ccRCC cell invasion and invadopodium maturation as a downstream effector of TGFβ1 signaling.","method":"Primary ccRCC cell cultures, TGFβ1 treatment, ubiquitination assay, 3D invasion assay, matrix degradation assay, siRNA knockdown","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — ubiquitination assay and functional invasion readout in primary cells; single lab with two orthogonal mechanistic methods","pmids":["36310399"],"is_preprint":false},{"year":2023,"finding":"Abl2 promotes microtubule nucleation by undergoing liquid-liquid phase separation (LLPS) and forming co-condensates with tubulin via its C-terminal half; Abl2 binds the MT lattice adjacent to damage sites, facilitates MT repair by recruiting fresh tubulin, and increases MT rescue frequency and lifetime. The Abl2Δ688-790 isoform retains MT-lattice binding but cannot bind tubulin, promote nucleation, or increase rescue. Cryo-EM supports engagement of tubulin C-terminal tails along an extended MT lattice conformation at damage sites. MT reassembly after nocodazole washout is severely impaired in Abl2 KO cells and rescued by Abl2 but not Abl2Δ688-790.","method":"In vitro MT dynamics reconstitution (TIRF), LLPS assay, cryo-EM, Abl2 KO COS-7 cells with nocodazole washout, domain deletion mutant rescue","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution, cryo-EM structure, LLPS assay, domain mutant analysis, and KO cell rescue; multiple orthogonal methods in a single rigorous study","pmids":["37858340"],"is_preprint":false},{"year":2025,"finding":"The SH3 domain (exon 3) of Abl2 is essential for the efficacy of STAMP inhibitors (asciminib and TERN-701) targeting the Abl2 myristate pocket; different myristate pocket residues impact asciminib binding to Abl2 versus Abl1, predicting distinct resistance mutations in ABL2-rearranged ALL.","method":"Truncated ZC3HAV1::ABL2 isoforms, in vitro sensitivity assays, in silico molecular modeling, in vivo mouse model","journal":"Blood neoplasia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain truncation rescue experiments and in vivo model; computational modeling supporting structural interpretation; single lab","pmids":["40678005"],"is_preprint":false},{"year":2026,"finding":"FBXO31 directly interacts with ABL2 via its F-box motif and promotes ABL2 ubiquitination and proteasomal degradation, suppressing ABL2-driven TNBC cell proliferation, migration, invasion, and inhibition of xCT-mediated ferroptosis.","method":"Co-immunoprecipitation, ubiquitination assay, overexpression/knockdown rescue experiments, ferroptosis assays, mouse xenograft","journal":"American journal of translational research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — co-IP of FBXO31-ABL2 interaction, ubiquitination assay, and functional rescue; single lab","pmids":["42170439"],"is_preprint":false},{"year":2000,"finding":"A chromosomal t(1;12)(q25;p13) translocation fuses ETV6 to ARG (ABL2), producing ETV6/ARG fusion transcripts that encode a protein containing the ETV6 PNT oligomerization domain and all functional ARG domains including the tyrosine kinase domain, identifying the first involvement of ARG in human leukemia.","method":"RT-PCR cloning of fusion transcripts, sequencing, characterization of open reading frame from AML-M3 cell line","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — RT-PCR identification and sequence characterization of fusion transcript; replicated in second cell line (PMID:12406085)","pmids":["10706884","12406085"],"is_preprint":false}],"current_model":"ABL2/Arg is a non-receptor tyrosine kinase that directly binds integrin β1 tails and receptor tyrosine kinases (PDGFRβ, EGFR, plexin A1) to become activated, whereupon it phosphorylates substrates including p190RhoGAP (inactivating RhoA to collapse the cytoskeleton), cortactin (stabilizing actin filaments and promoting Arp2/3-mediated branching), MNRR1/CHCHD2 (stimulating mitochondrial respiration), and HSF1 (driving a pro-metastatic transcriptional program); structurally, ABL2 uses its SH2, SH3, kinase, IWLEQ, and CH actin-binding domains to regulate actin filament dynamics, microtubule nucleation and repair via LLPS with tubulin, dendritic spine stability, and vascular barrier integrity, and is subject to ubiquitin-mediated degradation by FBXO31 and to activation by PDGFRβ phosphorylation at SH3/kinase linker residues."},"narrative":{"mechanistic_narrative":"ABL2/Arg is a non-receptor tyrosine kinase that couples cell-surface receptor signaling to remodeling of the actin and microtubule cytoskeletons, thereby controlling cell migration, dendritic spine and dendrite stability, and vascular barrier integrity [PMID:18660502, PMID:23365224, PMID:33770321]. The kinase is switched on by direct engagement with upstream receptors: its SH2 domain binds the integrin β1 cytoplasmic tail (with reciprocal phosphorylation of β1 Tyr-783) and phosphotyrosine Y771 of PDGFRβ, the latter triggering phosphorylation of SH3/kinase-linker tyrosines (Y116, Y161, Y272, Y310) that activate Arg kinase activity [PMID:25694433, PMID:34144039]. Once active, Arg phosphorylates p190RhoGAP to inactivate RhoA and collapse the actin cytoskeleton downstream of the plexin A1/SEMA3F/NRP2 axis [PMID:18660502], while a separate C-terminal module — the (I/L)WEQ actin-binding and CH domains — directly stabilizes actin filaments, drives Arp2/3-mediated branching, and cooperates with cortactin to maintain stable filament pools [PMID:22849492, PMID:25540195]. The same C-terminal half promotes microtubule nucleation and damage-site repair by forming liquid-liquid phase-separated co-condensates with tubulin [PMID:37858340]. In neurons, Arg sustains dendrite arbor and dendritic spine stability through parallel RhoA-dependent and cortactin-tethering mechanisms, shaping synaptic maturation and plasticity [PMID:23365224, PMID:27335408, PMID:33622779]. Beyond the cytoskeleton, Arg phosphorylates the mitochondrial protein MNRR1/CHCHD2 to stimulate respiration [PMID:27913209], and drives pro-metastatic transcriptional programs by phosphorylating TAZ and stabilizing HSF1 [PMID:31825826, PMID:33318173]. Arg abundance is controlled by ubiquitin-mediated degradation, including by the F-box protein FBXO31 [PMID:42170439]. A t(1;12) translocation fusing ETV6 to ABL2 implicates the kinase in human leukemia [PMID:10706884, PMID:12406085], and structural studies define how ATP-competitive and allosteric/myristate-pocket inhibitors engage its catalytic domain [PMID:21417343, PMID:25849507, PMID:40678005].","teleology":[{"year":2000,"claim":"Established the first link between ABL2/ARG and human malignancy by identifying a leukemia-associated fusion that retains the full ARG kinase.","evidence":"RT-PCR cloning and sequencing of ETV6/ARG fusion transcripts from an AML-M3 cell line","pmids":["10706884","12406085"],"confidence":"Medium","gaps":["Did not test the transforming activity of the fusion protein","Mechanism of ETV6 PNT-driven oligomerization/activation not demonstrated functionally"]},{"year":2008,"claim":"Answered how ABL2 transduces guidance-receptor signals into cytoskeletal collapse, placing it downstream of plexin A1 and upstream of RhoA.","evidence":"Co-IP, siRNA, kinase-dead mutant, and RhoA GTP/GDP activity assays with in vitro phosphorylation of p190RhoGAP","pmids":["18660502"],"confidence":"High","gaps":["Did not resolve the structural basis of the plexin A1 interaction","In vivo migratory consequences not addressed"]},{"year":2011,"claim":"Provided atomic detail of the ABL2 catalytic domain bound to ATP-competitive and dual-site inhibitors, defining druggable conformations.","evidence":"X-ray co-crystal structures with imatinib, VX-680, and a triazole carbothioamide inhibitor","pmids":["21417343"],"confidence":"High","gaps":["Structures are of the isolated kinase domain, not full-length autoregulated protein","No catalytic-cycle or activation-loop dynamics captured"]},{"year":2012,"claim":"Clarified ABL2's paradoxical role in cancer, showing it promotes invasion/metastasis while suppressing primary tumor growth and Ras-MAPK signaling.","evidence":"shRNA knockdown in breast cancer xenografts with gene-expression, invasion, and intravasation readouts","pmids":["22777352"],"confidence":"Medium","gaps":["Molecular link between ABL2 and Ras-MAPK suppression not defined","Direct substrates driving the invasion program not identified"]},{"year":2012,"claim":"Identified a non-catalytic mechanism by which ABL2 enhances cortactin-actin binding through its CH domain.","evidence":"Actin co-sedimentation with Arg deletion mutants and fragments","pmids":["22849492"],"confidence":"Medium","gaps":["In vitro stoichiometry not linked to a cellular phenotype here","Whether kinase activity modulates this binding untested"]},{"year":2013,"claim":"Dissected two distinct cytoskeletal pathways by which ABL2 stabilizes neuronal architecture — RhoA-dependent dendrite stability versus cortactin-localization-dependent spine stability.","evidence":"shRNA, RhoA inhibition, NMDAR block, and cortactin-Arg actin-binding-domain fusion rescue in hippocampal neurons","pmids":["23365224"],"confidence":"High","gaps":["In vivo relevance addressed only in later work","Upstream activator in neurons not defined"]},{"year":2013,"claim":"Showed that endogenous ABL2 isoforms differ in localization and substrate effects, including a nuclear isoform that phosphorylates CrkII.","evidence":"Isoform transfection in COS-7, immunofluorescence, and phospho-CrkII/p190RhoGAP western blots","pmids":["23707396"],"confidence":"Medium","gaps":["Overexpression may not reflect endogenous isoform stoichiometry","Functional significance of nuclear CrkII phosphorylation unresolved"]},{"year":2014,"claim":"Reconstituted ABL2's direct biochemical actions on actin, defining filament stabilization, Arp2/3 branch stimulation, CH-domain autoinhibition, and cofilin-severing potentiation.","evidence":"In vitro TIRF actin assembly, depolymerization, branching, and cofilin-severing assays with purified proteins and deletion mutants","pmids":["25540195"],"confidence":"High","gaps":["How kinase signaling toggles these activities in cells not shown","Quantitative balance between branching and severing in vivo unknown"]},{"year":2015,"claim":"Defined the bipartite mechanism by which ABL2 directly binds and is activated by integrin β1, linking adhesion receptors to kinase activation.","evidence":"In vitro pulldowns, mutagenesis, kinase and binding assays, and cellular co-IP","pmids":["25694433"],"confidence":"High","gaps":["Downstream substrates engaged specifically by integrin-activated ABL2 not mapped","Structural model of the kinase-domain/β1-tail interface absent"]},{"year":2015,"claim":"Captured the dasatinib-bound ARG catalytic domain, revealing a DFG-in conformation without activation-loop phosphorylation.","evidence":"2.5 Å X-ray co-crystal structure of mouse ARG catalytic domain","pmids":["25849507"],"confidence":"High","gaps":["Isolated domain only; regulatory domains not present","Implications for inhibitor selectivity over ABL1 not functionally tested here"]},{"year":2016,"claim":"Extended ABL2 substrate scope into mitochondria, showing it phosphorylates MNRR1/CHCHD2 to promote COX binding and respiration, with disease-mutant validation.","evidence":"In vitro kinase assay, co-IP, fractionation, respiration measurement, and Q112H mutant analysis","pmids":["27913209"],"confidence":"Medium","gaps":["How ABL2 accesses the mitochondrial compartment not established","Fraction of cellular respiration controlled by this axis unquantified"]},{"year":2016,"claim":"Demonstrated in vivo that ABL2 is required for synaptic maturation, with its loss leaving immature GluN2B synapses and altered plasticity.","evidence":"Arg knockout mice with glutamate uncaging, electrophysiology, and spine morphometry","pmids":["27335408"],"confidence":"High","gaps":["Molecular substrates linking ABL2 to GluN2B retention not identified","Behavioral consequences not measured here"]},{"year":2017,"claim":"Connected stress-hormone signaling to ABL2, showing corticosterone lowers ABL2 and substrate phosphorylation while pharmacological activation rescues dendrite and behavioral deficits.","evidence":"Western blots in cortisol-treated mice, DPH activator rescue, dendrite morphology, and behavioral tests","pmids":["29107098"],"confidence":"Medium","gaps":["Mechanism by which corticosterone reduces ABL2 protein not defined","DPH specificity for ABL2 over ABL1 not fully controlled"]},{"year":2017,"claim":"Identified ABL2 as a FLT3-interacting kinase that selectively dampens AKT signaling downstream of oncogenic FLT3-ITD.","evidence":"SH2 domain array, co-IP, and Ba/F3 overexpression with phospho-signaling readouts","pmids":["28086240"],"confidence":"Medium","gaps":["Mechanism of selective AKT (not ERK/p38) suppression unresolved","Endogenous ABL2 contribution versus overexpression untested"]},{"year":2018,"claim":"Localized ABL2 to ventral actin waves and adhesion foci and showed its C-terminal half, not the kinase domain, drives this recruitment and lamellipodial control.","evidence":"TIRF live imaging, Abl2 KO cells, and N/C-terminal domain complementation","pmids":["30256707"],"confidence":"Medium","gaps":["Direct binding partner anchoring ABL2 to wave structures not pinpointed","Role of kinase activity in wave dynamics separate from recruitment unclear"]},{"year":2019,"claim":"Placed ABL2 in a TAZ-driven feed-forward loop required for brain metastasis, with ABL2 phosphorylating TAZ to promote its nuclear localization.","evidence":"shRNA of ABL2/AXL/TAZ, in vivo brain metastasis model, TAZ phosphorylation, and BBB-penetrant ABL inhibitor","pmids":["31825826"],"confidence":"Medium","gaps":["TAZ phosphosites targeted by ABL2 not mapped","Generalizability beyond lung adenocarcinoma not tested"]},{"year":2019,"claim":"Showed ABL2 isoforms differentially program fibroblast activation and ECM remodeling, with distinct roles in adhesion versus invasion.","evidence":"Isoform rescue in Arg−/− MEFs with proliferation, migration, focal-adhesion, and ECM contraction assays","pmids":["30837227"],"confidence":"Medium","gaps":["Molecular basis of isoform-specific outputs not defined","In vivo fibroblast relevance untested"]},{"year":2020,"claim":"Defined a non-catalytic ABL2 function in metastasis through direct SH3-domain binding and stabilization of HSF1, druggable by allosteric but not ATP-competitive inhibitors.","evidence":"Co-IP, SH3 binding assay, allosteric-vs-ATP-competitive inhibitor comparison, and transcriptional target measurement","pmids":["33318173"],"confidence":"Medium","gaps":["Structural detail of the noncanonical SH3-HSF1 interface absent","How SH3 binding stabilizes HSF1 protein mechanistically unclear"]},{"year":2020,"claim":"Implicated ABL2 in endocytic vesicle maturation, acting downstream of EGFR to shape endocytic pits during HPV16 uptake.","evidence":"Pharmacological ABL2/EGFR inhibition with microscopy of endocytic pits and virus uptake quantification","pmids":["32188731"],"confidence":"Medium","gaps":["Direct ABL2 substrates at endocytic sites not identified","Reliance on inhibitor specificity without genetic confirmation"]},{"year":2021,"claim":"Resolved how receptor tyrosine kinase signaling activates ABL2, mapping PDGFRβ binding to the ABL2 SH2 domain and identifying linker phosphosites whose mutation abolishes activation.","evidence":"In vitro binding/kinase assays, MS phosphosite mapping, and 4xF mutagenesis","pmids":["34144039"],"confidence":"High","gaps":["Structural model of how linker phosphorylation relieves autoinhibition not solved","Cellular substrates engaged after PDGFRβ activation not profiled here"]},{"year":2021,"claim":"Established the molecular requirement for ABL2 in dendritic spine stability via a cortactin-tethered stable actin pool sustained by synaptic activity.","evidence":"GFP-actin FRAP, Abl2 shRNA, interaction mutants, and activity manipulation in hippocampal neurons","pmids":["33622779"],"confidence":"High","gaps":["How synaptic activity drives cortactin enrichment mechanistically unresolved","Kinase activity requirement for stable pool maintenance not fully separated"]},{"year":2021,"claim":"Defined ABL2 as a regulator of endothelial barrier integrity, restraining cell spreading and adhesion through RhoA/Rac1 and contributing to inflammatory vascular leak.","evidence":"siRNA, RhoA/Rac1 activity assays, TEER, in vivo permeability assays, and patient microvessel staining","pmids":["33770321"],"confidence":"Medium","gaps":["Upstream inflammatory signal activating endothelial ABL2 not identified","Direct substrates mediating barrier disruption not mapped"]},{"year":2022,"claim":"Positioned ABL2 as a degradation-controlled downstream effector of TGFβ1 signaling driving invadopodium maturation in renal cancer.","evidence":"Primary ccRCC cultures, TGFβ1 treatment, ubiquitination and 3D invasion/matrix-degradation assays","pmids":["36310399"],"confidence":"Medium","gaps":["E3 ligase mediating TGFβ1/ROS-induced ABL2 degradation not identified","Direct invadopodial substrates of ABL2 unmapped"]},{"year":2023,"claim":"Revealed a kinase-independent ABL2 function in microtubule nucleation and repair via liquid-liquid phase separation with tubulin through its C-terminal half.","evidence":"In vitro MT dynamics reconstitution, LLPS assay, cryo-EM, and KO/domain-mutant rescue in cells","pmids":["37858340"],"confidence":"High","gaps":["Regulation of ABL2 condensate formation in cells not defined","Crosstalk between MT and actin functions of the C-terminal half unresolved"]},{"year":2024,"claim":"Identified FBXO31 as a direct E3-ligase regulator of ABL2 abundance, linking ABL2 degradation to suppression of TNBC growth and ferroptosis resistance.","evidence":"Co-IP, ubiquitination assay, rescue experiments, ferroptosis assays, and xenografts","pmids":["42170439"],"confidence":"Medium","gaps":["Degron on ABL2 recognized by FBXO31 not mapped","Whether this is the same axis as TGFβ1-induced degradation untested"]},{"year":2025,"claim":"Showed the ABL2 SH3 domain and specific myristate-pocket residues govern STAMP/allosteric inhibitor efficacy and predict distinct resistance in ABL2-rearranged leukemia.","evidence":"Truncated ZC3HAV1::ABL2 isoforms, in vitro sensitivity, in silico modeling, and in vivo mouse model","pmids":["40678005"],"confidence":"Medium","gaps":["Predicted resistance mutations not yet clinically validated","Structural basis of ABL2-vs-ABL1 myristate-pocket selectivity inferred computationally"]},{"year":null,"claim":"It remains unresolved how ABL2's distinct outputs — RhoA inactivation, direct actin/microtubule remodeling, mitochondrial and transcriptional substrate phosphorylation — are selected and integrated by a single activated kinase in a given cellular context.","evidence":"No single study in the corpus reconstitutes substrate-selection logic across compartments","pmids":[],"confidence":"Low","gaps":["No unified model of context-dependent substrate selection","Interplay between kinase-dependent and kinase-independent (LLPS, scaffolding) functions undefined","Structural mechanism of full-length autoregulation unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,7,9,14,20]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,7,9,20]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[3,6,13,22]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,16]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[5,13]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[5]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[6,13,22]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[9]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[7,18]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,7,20]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,14,16,25]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[4,10,19]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[14,16]}],"complexes":[],"partners":["CTTN","PDGFRB","ITGB1","PLXNA1","CHCHD2","HSF1","FBXO31","FLT3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P42684","full_name":"Tyrosine-protein kinase ABL2","aliases":["Abelson murine leukemia viral oncogene homolog 2","Abelson tyrosine-protein kinase 2","Abelson-related gene protein","Tyrosine-protein kinase ARG"],"length_aa":1182,"mass_kda":128.3,"function":"Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (involved in signaling); or TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and regulates actin cytoskeletal structure through its F-actin-bundling activity. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as CRK, CRKL, DOK1 or ARHGAP35. Adhesion-dependent phosphorylation of ARHGAP35 promotes its association with RASA1, resulting in recruitment of ARHGAP35 to the cell periphery where it inhibits RHO. Phosphorylates multiple receptor tyrosine kinases like PDGFRB and other substrates which are involved in endocytosis regulation such as RIN1. In brain, may regulate neurotransmission by phosphorylating proteins at the synapse. ABL2 also acts as a regulator of multiple pathological signaling cascades during infection. Pathogens can highjack ABL2 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Positively regulates chemokine-mediated T-cell migration, polarization, and homing to lymph nodes and immune-challenged tissues, potentially via activation of NEDD9/HEF1 and RAP1 (By similarity)","subcellular_location":"Cytoplasm, cytoskeleton","url":"https://www.uniprot.org/uniprotkb/P42684/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ABL2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"NCKAP1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ABL2","total_profiled":1310},"omim":[{"mim_id":"616349","title":"SORBIN AND SH3 DOMAINS-CONTAINING PROTEIN 2; SORBS2","url":"https://www.omim.org/entry/616349"},{"mim_id":"606607","title":"PROTEASOME SUBUNIT, ALPHA-TYPE, 7; PSMA7","url":"https://www.omim.org/entry/606607"},{"mim_id":"601296","title":"MUSCLE, SKELETAL, RECEPTOR TYROSINE KINASE; MUSK","url":"https://www.omim.org/entry/601296"},{"mim_id":"600618","title":"ETS VARIANT TRANSCRIPTION FACTOR 6; ETV6","url":"https://www.omim.org/entry/600618"},{"mim_id":"189980","title":"ABL PROTOONCOGENE 1, NONRECEPTOR TYROSINE KINASE; ABL1","url":"https://www.omim.org/entry/189980"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"},{"location":"Intermediate filaments","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ABL2"},"hgnc":{"alias_symbol":["ARG"],"prev_symbol":["ABLL"]},"alphafold":{"accession":"P42684","domains":[{"cath_id":"2.30.30.40","chopping":"94-168","consensus_level":"medium","plddt":84.2359,"start":94,"end":168},{"cath_id":"3.30.505.10","chopping":"174-265","consensus_level":"medium","plddt":92.1435,"start":174,"end":265},{"cath_id":"3.30.200.20","chopping":"282-364","consensus_level":"medium","plddt":87.3893,"start":282,"end":364},{"cath_id":"1.10.510.10","chopping":"372-558","consensus_level":"medium","plddt":92.183,"start":372,"end":558},{"cath_id":"1.20.120.330","chopping":"1083-1182","consensus_level":"high","plddt":84.9985,"start":1083,"end":1182}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P42684","model_url":"https://alphafold.ebi.ac.uk/files/AF-P42684-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P42684-F1-predicted_aligned_error_v6.png","plddt_mean":59.22},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ABL2","jax_strain_url":"https://www.jax.org/strain/search?query=ABL2"},"sequence":{"accession":"P42684","fasta_url":"https://rest.uniprot.org/uniprotkb/P42684.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P42684/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P42684"}},"corpus_meta":[{"pmid":"22777352","id":"PMC_22777352","title":"Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22777352","citation_count":103,"is_preprint":false},{"pmid":"18660502","id":"PMC_18660502","title":"ABL2/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human glioma cells.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18660502","citation_count":93,"is_preprint":false},{"pmid":"10706884","id":"PMC_10706884","title":"A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25;p13) translocation.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10706884","citation_count":86,"is_preprint":false},{"pmid":"36310399","id":"PMC_36310399","title":"The cross-talk between Abl2 tyrosine kinase and TGFβ1 signalling modulates the invasion of clear cell Renal Cell Carcinoma cells.","date":"2022","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/36310399","citation_count":77,"is_preprint":false},{"pmid":"24464651","id":"PMC_24464651","title":"miR-20a promotes prostate cancer invasion and migration through targeting ABL2.","date":"2014","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24464651","citation_count":64,"is_preprint":false},{"pmid":"23365224","id":"PMC_23365224","title":"Abl2/Arg controls dendritic spine and dendrite arbor stability via distinct cytoskeletal control pathways.","date":"2013","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23365224","citation_count":55,"is_preprint":false},{"pmid":"31825826","id":"PMC_31825826","title":"A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31825826","citation_count":45,"is_preprint":false},{"pmid":"26766902","id":"PMC_26766902","title":"MicroRNA-125a-5p modulates human cervical carcinoma proliferation and migration by targeting ABL2.","date":"2015","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26766902","citation_count":44,"is_preprint":false},{"pmid":"25694433","id":"PMC_25694433","title":"Direct interactions with the integrin β1 cytoplasmic tail activate the Abl2/Arg kinase.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25694433","citation_count":36,"is_preprint":false},{"pmid":"21417343","id":"PMC_21417343","title":"Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class.","date":"2011","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21417343","citation_count":34,"is_preprint":false},{"pmid":"25540195","id":"PMC_25540195","title":"Abl2/Abl-related gene stabilizes actin filaments, stimulates actin branching by actin-related protein 2/3 complex, and promotes actin filament severing by cofilin.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25540195","citation_count":33,"is_preprint":false},{"pmid":"12406085","id":"PMC_12406085","title":"Identification of an ETV6-ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line.","date":"2002","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/12406085","citation_count":31,"is_preprint":false},{"pmid":"32999756","id":"PMC_32999756","title":"Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance.","date":"2020","source":"Experimental hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32999756","citation_count":29,"is_preprint":false},{"pmid":"22849492","id":"PMC_22849492","title":"Arg/Abl2 modulates the affinity and stoichiometry of binding of cortactin to F-actin.","date":"2012","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22849492","citation_count":28,"is_preprint":false},{"pmid":"27913209","id":"PMC_27913209","title":"Abl2 kinase phosphorylates Bi-organellar regulator MNRR1 in mitochondria, stimulating respiration.","date":"2016","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/27913209","citation_count":28,"is_preprint":false},{"pmid":"33318173","id":"PMC_33318173","title":"The ABL2 kinase regulates an HSF1-dependent transcriptional program required for lung adenocarcinoma brain metastasis.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33318173","citation_count":26,"is_preprint":false},{"pmid":"32188731","id":"PMC_32188731","title":"Epidermal Growth Factor Receptor and Abl2 Kinase Regulate Distinct Steps of Human Papillomavirus 16 Endocytosis.","date":"2020","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/32188731","citation_count":25,"is_preprint":false},{"pmid":"33770321","id":"PMC_33770321","title":"Depletion of Arg/Abl2 improves endothelial cell adhesion and prevents vascular leak during inflammation.","date":"2021","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/33770321","citation_count":24,"is_preprint":false},{"pmid":"2567701","id":"PMC_2567701","title":"Mapping of Abll within a conserved linkage group on distal mouse chromosome 1 syntenic with human chromosome 1 using an interspecific cross.","date":"1989","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/2567701","citation_count":20,"is_preprint":false},{"pmid":"27335408","id":"PMC_27335408","title":"Disruption of Coordinated Presynaptic and Postsynaptic Maturation Underlies the Defects in Hippocampal Synapse Stability and Plasticity in Abl2/Arg-Deficient Mice.","date":"2016","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27335408","citation_count":20,"is_preprint":false},{"pmid":"32196586","id":"PMC_32196586","title":"Circular RNA-ABCB10 suppresses hepatocellular carcinoma progression through upregulating NRP1/ABL2 via sponging miR-340-5p/miR-452-5p.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32196586","citation_count":19,"is_preprint":false},{"pmid":"33087469","id":"PMC_33087469","title":"The NSs Protein Encoded by the Virulent Strain of Rift Valley Fever Virus Targets the Expression of Abl2 and the Actin Cytoskeleton of the Host, Affecting Cell Mobility, Cell Shape, and Cell-Cell Adhesion.","date":"2020","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/33087469","citation_count":19,"is_preprint":false},{"pmid":"33722655","id":"PMC_33722655","title":"Bone marrow mesenchymal stem cells-derived exosomal microRNA-19b-1-5p reduces proliferation and raises apoptosis of bladder cancer cells via targeting ABL2.","date":"2021","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/33722655","citation_count":18,"is_preprint":false},{"pmid":"36104322","id":"PMC_36104322","title":"Circular RNA circPGD contributes to gastric cancer progression via the sponging miR-16-5p/ABL2 axis and encodes a novel PGD-219aa protein.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/36104322","citation_count":17,"is_preprint":false},{"pmid":"29107098","id":"PMC_29107098","title":"Corticosteroid-induced dendrite loss and behavioral deficiencies can be blocked by activation of Abl2/Arg kinase.","date":"2017","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/29107098","citation_count":16,"is_preprint":false},{"pmid":"29767389","id":"PMC_29767389","title":"High Expression of ABL2 Suppresses Apoptosis in Gastric Cancer.","date":"2018","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29767389","citation_count":15,"is_preprint":false},{"pmid":"24759231","id":"PMC_24759231","title":"Gleevec/imatinib, an ABL2 kinase inhibitor, protects tumor and endothelial cells from semaphorin-induced cytoskeleton collapse and loss of cell motility.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24759231","citation_count":15,"is_preprint":false},{"pmid":"28086240","id":"PMC_28086240","title":"ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28086240","citation_count":12,"is_preprint":false},{"pmid":"32196963","id":"PMC_32196963","title":"miR-143 inhibits renal cell carcinoma cells metastatic potential by suppressing ABL2.","date":"2020","source":"The Kaohsiung journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32196963","citation_count":11,"is_preprint":false},{"pmid":"37781087","id":"PMC_37781087","title":"ABL1 and ABL2 promote medulloblastoma leptomeningeal dissemination.","date":"2023","source":"Neuro-oncology advances","url":"https://pubmed.ncbi.nlm.nih.gov/37781087","citation_count":9,"is_preprint":false},{"pmid":"33622779","id":"PMC_33622779","title":"Abl2:Cortactin Interactions Regulate Dendritic Spine Stability via Control of a Stable Filamentous Actin Pool.","date":"2021","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33622779","citation_count":9,"is_preprint":false},{"pmid":"39298063","id":"PMC_39298063","title":"Cancer-associated fibroblast-derived exosome Leptin promotes malignant biological lineage in pancreatic ductal adenocarcinoma by regulating ABL2 via miR-224-3p.","date":"2024","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/39298063","citation_count":9,"is_preprint":false},{"pmid":"37858340","id":"PMC_37858340","title":"Abl2 repairs microtubules and phase separates with tubulin to promote microtubule nucleation.","date":"2023","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/37858340","citation_count":8,"is_preprint":false},{"pmid":"25849507","id":"PMC_25849507","title":"Structure of the ABL2/ARG kinase in complex with dasatinib.","date":"2015","source":"Acta crystallographica. Section F, Structural biology communications","url":"https://pubmed.ncbi.nlm.nih.gov/25849507","citation_count":8,"is_preprint":false},{"pmid":"37587494","id":"PMC_37587494","title":"Bone mesenchymal stem cell extracellular vesicles delivered miR let-7-5p alleviate endothelial glycocalyx degradation and leakage via targeting ABL2.","date":"2023","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/37587494","citation_count":8,"is_preprint":false},{"pmid":"30256707","id":"PMC_30256707","title":"Abl2 is recruited to ventral actin waves through cytoskeletal interactions to promote lamellipodium extension.","date":"2018","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/30256707","citation_count":8,"is_preprint":false},{"pmid":"23707396","id":"PMC_23707396","title":"One isoform of Arg/Abl2 tyrosine kinase is nuclear and the other seven cytosolic isoforms differently modulate cell morphology, motility and the cytoskeleton.","date":"2013","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/23707396","citation_count":8,"is_preprint":false},{"pmid":"33550941","id":"PMC_33550941","title":"microRNA-1296 Inhibits Glioma Cell Growth by Targeting ABL2.","date":"2021","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/33550941","citation_count":7,"is_preprint":false},{"pmid":"30837227","id":"PMC_30837227","title":"The 1ALCTL and 1BLCTL isoforms of Arg/Abl2 induce fibroblast activation and extra cellular matrix remodelling differently.","date":"2019","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/30837227","citation_count":7,"is_preprint":false},{"pmid":"29550892","id":"PMC_29550892","title":"A Role for the Non-Receptor Tyrosine Kinase Abl2/Arg in Experimental Neuroinflammation.","date":"2018","source":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29550892","citation_count":6,"is_preprint":false},{"pmid":"36689065","id":"PMC_36689065","title":"Abl2 Kinase Differentially Regulates iGluRs Current Activity and Synaptic Localization.","date":"2023","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/36689065","citation_count":5,"is_preprint":false},{"pmid":"35355231","id":"PMC_35355231","title":"Circ_0000263 facilitates the proliferation and inhibits the apoptosis of cervical cancer depending on the regulation of miR-1179/ABL2 axis.","date":"2022","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/35355231","citation_count":5,"is_preprint":false},{"pmid":"34144039","id":"PMC_34144039","title":"Platelet-derived growth factor receptor beta activates Abl2 via direct binding and phosphorylation.","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34144039","citation_count":4,"is_preprint":false},{"pmid":"40678005","id":"PMC_40678005","title":"Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain.","date":"2025","source":"Blood neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/40678005","citation_count":4,"is_preprint":false},{"pmid":"37376546","id":"PMC_37376546","title":"The S2 Subunit of Infectious Bronchitis Virus Affects Abl2-Mediated Syncytium Formation.","date":"2023","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/37376546","citation_count":4,"is_preprint":false},{"pmid":"38496838","id":"PMC_38496838","title":"Long noncoding RNA LINC00858 aggravates the progression of esophageal squamous cell carcinoma via regulating the miR-425-5p/ABL2 axis.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/38496838","citation_count":4,"is_preprint":false},{"pmid":"38109857","id":"PMC_38109857","title":"A Case Report of Infant-Type Hemispheric Glioma with a Novel GAB1-ABL2 Kinase Fusion Treated with Dasatinib.","date":"2023","source":"Pediatric neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/38109857","citation_count":4,"is_preprint":false},{"pmid":"37479901","id":"PMC_37479901","title":"Tumor-suppressive action of miR-30a-5p in lung adenocarcinoma correlates with ABL2 inhibition and PI3K/AKT pathway inactivation.","date":"2023","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/37479901","citation_count":2,"is_preprint":false},{"pmid":"40282426","id":"PMC_40282426","title":"miR-143-3p Promotes TSCM Differentiation and Inhibits Progressive T Cell Differentiation via Inhibiting ABL2 and PAG1.","date":"2025","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/40282426","citation_count":2,"is_preprint":false},{"pmid":"31189154","id":"PMC_31189154","title":"A Novel Case of ABL2 Chromosomal Rearrangement in High-Risk B-Cell Acute Lymphoblastic Leukemia.","date":"2019","source":"Journal of the Association of Genetic Technologists","url":"https://pubmed.ncbi.nlm.nih.gov/31189154","citation_count":2,"is_preprint":false},{"pmid":"38697301","id":"PMC_38697301","title":"Impact of Abl2/Arg deficiency on anxiety and depressive behaviors in mice.","date":"2024","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/38697301","citation_count":1,"is_preprint":false},{"pmid":"39308677","id":"PMC_39308677","title":"High expression of ABL2 promotes gastric cancer cells migration, invasion and proliferation via the TGF-β and YAP signaling pathways.","date":"2024","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39308677","citation_count":1,"is_preprint":false},{"pmid":"41444785","id":"PMC_41444785","title":"Identification of bioactive phytoconstituents as promising ABL2 inhibitors using virtual screening and molecular dynamics simulation.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/41444785","citation_count":1,"is_preprint":false},{"pmid":"40911967","id":"PMC_40911967","title":"Targeting melanoma resistance: Novel oxindole and non-oxindole-based benzimidazole derivatives as potent dual inhibitors of BRAFV600E and ABL2 kinases.","date":"2025","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40911967","citation_count":1,"is_preprint":false},{"pmid":"26505392","id":"PMC_26505392","title":"Effect of Bcl-2-siRNA on proliferation and apoptosis of pediatric acute B lymphoblastic leukemia (A-BLL) cells.","date":"2015","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/26505392","citation_count":1,"is_preprint":false},{"pmid":"41782643","id":"PMC_41782643","title":"Identification of a Novel, Oncogenic and Targetable TPR::ABL2 Fusion Gene in T-Cell Acute Lymphoblastic Leukaemia.","date":"2026","source":"EJHaem","url":"https://pubmed.ncbi.nlm.nih.gov/41782643","citation_count":0,"is_preprint":false},{"pmid":"41602364","id":"PMC_41602364","title":"LncRNA DANCR promotes ABL2-mediated metastasis via decoying of miR-125a-5p in high-risk neuroblastoma.","date":"2026","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41602364","citation_count":0,"is_preprint":false},{"pmid":"42170439","id":"PMC_42170439","title":"FBXO31-induced ABL2 ubiquitination increases cystine-glutamate antiporter-mediated ferroptosis and inhibits malignant progression in triple-negative breast cancer.","date":"2026","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/42170439","citation_count":0,"is_preprint":false},{"pmid":"14990050","id":"PMC_14990050","title":"[Clonal expansion of TCR Vbeta subfamily T cells induced by bcr3-abl2 peptide].","date":"2004","source":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","url":"https://pubmed.ncbi.nlm.nih.gov/14990050","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.05.19.25327541","title":"Missense<i>ABI2</i>variants linked to a neurodevelopmental disorder with intellectual disability, epilepsy, hypoplasia of the corpus callosum, and white matter abnormalities","date":"2025-05-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.19.25327541","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":32723,"output_tokens":7018,"usd":0.10172,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16143,"output_tokens":7330,"usd":0.131983,"stage2_stop_reason":"end_turn"},"total_usd":0.233703,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"ABL2/ARG directly binds plexin A1 (but not a cytoplasmic-domain-lacking plexin A1 mutant) downstream of SEMA3F/NRP2 receptor complex, then phosphorylates and activates p190RhoGAP, which inactivates RhoA (GTP→GDP), resulting in cytoskeletal collapse and inhibition of cell migration. Cells expressing an ABL2 kinase-dead mutant or treated with ABL2 siRNA failed to inactivate RhoA.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, kinase-dead mutant overexpression, RhoA activity assay (GTP/GDP), in vitro phosphorylation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding assay with domain mutant, kinase-dead mutant, siRNA, and biochemical RhoA activity readout in a single focused study; independently supported by follow-up papers (PMID:24759231)\",\n      \"pmids\": [\"18660502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structures of ABL2 kinase domain in complex with imatinib, VX-680 (tozasertib), and a type I triazole carbothioamide inhibitor were solved. Imatinib binds both the ATP-binding site of the inactive kinase and the regulatory myristate-binding site. VX-680-bound and type-I-inhibitor-bound structures reveal a DFG motif in a conformation intermediate between active and inactive states.\",\n      \"method\": \"X-ray crystallography (co-crystal structures)\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — three independent co-crystal structures in one rigorous structural study\",\n      \"pmids\": [\"21417343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Arg/Abl2 knockdown in breast cancer cells increases Ras-MAPK signaling and proliferation-associated gene expression while decreasing invasion-associated gene expression, demonstrating that Arg promotes tumor cell invasion/intravasation/metastasis in vivo while simultaneously suppressing tumor growth.\",\n      \"method\": \"shRNA knockdown in xenograft mouse model, gene expression analysis, in vivo invasion and intravasation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo xenograft with multiple phenotypic readouts (proliferation, invasion, intravasation, metastasis) and pathway analysis; single lab\",\n      \"pmids\": [\"22777352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Arg/Abl2 increases the stoichiometry of cortactin binding to F-actin at saturation, and the Arg C-terminal calponin homology (CH) domain is necessary and sufficient for this effect. Arg–cortactin protein–protein interactions are required for optimal cortactin–actin affinity.\",\n      \"method\": \"Actin co-sedimentation assays with Arg deletion mutants and fragments\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro reconstitution with defined deletion mutants, single lab, multiple constructs tested\",\n      \"pmids\": [\"22849492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Arg knockdown in hippocampal neurons destabilizes dendrite arbors via a RhoA-dependent mechanism, and destabilizes dendritic spines via an NMDA receptor-dependent relocalization of cortactin from spines; forcing cortactin into spines via fusion to Arg's actin-binding region prevents spine loss, demonstrating two distinct cytoskeletal control pathways for spine vs. dendrite stability.\",\n      \"method\": \"shRNA knockdown in cultured hippocampal neurons, live imaging, RhoA inhibition, NMDA receptor block, cortactin–Arg actin-binding domain fusion rescue\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal genetic and pharmacological interventions with specific phenotypic rescue in a single rigorous study\",\n      \"pmids\": [\"23365224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Eight full-length Arg/Abl2 isoforms are endogenously expressed in human cells; the 1BSCTS isoform has nuclear distribution and phosphorylates CrkII in the nucleus, while the other seven isoforms are cytoplasmic. Isoforms 1BLCTL, 1BSCTL, and 1ASCTS decrease stress fibers and increase p190RhoGAP phosphorylation, whereas other isoforms induce different morphological effects without reducing stress fibers.\",\n      \"method\": \"Isoform transfection in COS-7 cells, immunofluorescence localization, phospho-CrkII and phospho-p190RhoGAP western blotting\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — systematic isoform overexpression with multiple readouts; single lab\",\n      \"pmids\": [\"23707396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Arg/Abl2 stabilizes actin filaments against depolymerization via its internal (I/L)WEQ actin-binding domain, stimulates Arp2/3-mediated actin branch formation (requiring the IWLEQ domain; autoinhibition by the CH domain revealed by ArgΔCH), and potentiates cofilin-mediated actin filament severing; cortactin cooperates with Arg to stabilize filaments and attenuates Arg-enhanced cofilin severing.\",\n      \"method\": \"In vitro TIRF microscopy actin assembly assays, actin depolymerization assays, branching assays with purified Arp2/3, cofilin severing assays; Arg domain deletion mutants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple reconstituted in vitro assays with purified proteins and defined deletion mutants in a single rigorous study\",\n      \"pmids\": [\"25540195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The Arg kinase domain directly binds a lysine-rich membrane-proximal segment of the integrin β1 cytoplasmic tail; Arg phosphorylates β1 tail Tyr-783; the Arg SH2 domain then engages this phospho-Tyr-783 region; these interactions mediate direct Arg–β1 integrin binding in vitro and in cells, and activate Arg kinase activity.\",\n      \"method\": \"In vitro pulldown/binding assays, site-directed mutagenesis, in vitro kinase assay, co-immunoprecipitation from cells, kinase activity measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro binding reconstitution, mutagenesis, kinase activity assay, and cell-based co-IP; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"25694433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structure of mouse ARG/Abl2 catalytic domain in complex with dasatinib at 2.5 Å resolution; dasatinib-bound ARG adopts a DFG-in conformation despite being non-phosphorylated on the activation-loop tyrosine, with a relatively open P-loop conformation compared to other ABL family inhibitor complexes.\",\n      \"method\": \"X-ray crystallography (co-crystal structure at 2.5 Å)\",\n      \"journal\": \"Acta crystallographica. Section F, Structural biology communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — high-resolution co-crystal structure with structural analysis; single study\",\n      \"pmids\": [\"25849507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Abl2 kinase phosphorylates MNRR1 (CHCHD2) at tyrosine-99 within mitochondria; this phosphorylation promotes MNRR1 binding to cytochrome c oxidase (COX) and stimulates respiration. A disease-associated Q112H MNRR1 mutation impairs interaction with Abl2, reduces tyrosine phosphorylation, and causes defective respiration.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, subcellular fractionation, respiration measurement, disease mutant analysis\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical phosphorylation assay, co-IP, functional respiration readout, and disease-mutant validation; single lab\",\n      \"pmids\": [\"27913209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Loss of Abl2/Arg kinase in vivo yields a subpopulation of high-release-probability, GluN2B-containing immature hippocampal synapses that persist into early adulthood; these synapses show elevated NMDA receptor currents and enlarged spine heads. As arg−/− mice age, these synapses increase in proportion coinciding with net synapse loss, and both LTP and LTD become significantly altered by P42.\",\n      \"method\": \"Arg knockout mice, focal glutamate uncaging, electrophysiology (mEPSC, LTP, LTD), immunostaining for GluN2B, morphological spine analysis\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with multiple orthogonal electrophysiological and morphological readouts in vivo; rigorous study\",\n      \"pmids\": [\"27335408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Corticosterone exposure reduces Abl2/Arg protein levels and phosphorylation of its substrates p190RhoGAP and cortactin in hippocampal neurons, preceding dendrite arbor atrophy; pharmacological activation of Arg kinase with a small-molecule activator (DPH) corrects dendrite arbor simplification and corticosterone-induced behavioral deficits.\",\n      \"method\": \"Western blotting for Arg and substrate phosphorylation in cortisol-treated mice, pharmacological Arg kinase activation with DPH, dendritic morphology analysis, behavioral tests\",\n      \"journal\": \"Molecular and cellular neurosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological activation rescue with specific phenotypic readouts, western blot for substrate phosphorylation; single lab\",\n      \"pmids\": [\"29107098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ABL2 overexpression in FLT3-ITD-expressing Ba/F3 cells partially suppresses FLT3-ITD-induced proliferation and colony formation by blocking AKT phosphorylation without affecting ERK1/2 or p38, or altering FLT3 kinase activity, ubiquitination or stability. ABL2 was identified as a FLT3 interacting protein by SH2 domain array screen.\",\n      \"method\": \"SH2 domain array screen, co-immunoprecipitation, Ba/F3 cell overexpression, proliferation and colony formation assays, phospho-AKT/ERK/p38 western blotting\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — SH2 domain screen plus functional overexpression with multiple signaling readouts; single lab\",\n      \"pmids\": [\"28086240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Abl2 localizes with cortactin at wave-like ventral actin structures at the lamellum-lamellipodium interface and at cortactin-positive foci co-localizing with integrin β3 and paxillin; the Abl2 C-terminal half (actin- and microtubule-binding domains, not the kinase domain) is necessary and sufficient for recruitment to these wave structures and for supporting normal lamellipodium size.\",\n      \"method\": \"TIRF microscopy live imaging, Abl2 knockout cells, domain complementation with N- and C-terminal Abl2 halves, immunofluorescence co-localization\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct live imaging with knockout rescue and domain analysis; single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"30256707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The TAZ transcriptional co-activator drives expression of ABL2 and AXL in lung adenocarcinoma cells; ABL2 in turn phosphorylates TAZ to promote its nuclear localization, establishing an autocrine AXL-ABL2-TAZ feed-forward loop required for brain metastasis colonization. Knockdown of ABL2 or pharmacological inhibition with a BBB-penetrant ABL allosteric inhibitor markedly decreases brain metastases.\",\n      \"method\": \"shRNA knockdown of ABL2/AXL/TAZ, in vivo brain metastasis mouse model, TAZ phosphorylation assay, pharmacological ABL allosteric inhibitor treatment, transcriptional reporter assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple knockdowns plus pharmacological intervention in in vivo model with mechanistic phosphorylation readout; single lab\",\n      \"pmids\": [\"31825826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The 1ALCTL and 1BLCTL Arg/Abl2 isoforms differentially regulate fibroblast activation and ECM remodeling: 1BLCTL promotes proliferation, migration/invasion, and induces a tumor-supportive milieu, while 1ALCTL maintains active focal adhesions and cell adhesion. Both isoforms support myofibroblast features including ECM contraction and stiffness.\",\n      \"method\": \"Arg isoform rescue in Arg−/− MEFs, proliferation/migration/invasion assays, focal adhesion analysis, ECM contraction assays\",\n      \"journal\": \"Biology open\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — isoform-specific rescue experiments with multiple cellular readouts; single lab\",\n      \"pmids\": [\"30837227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ABL2 tyrosine kinase is identified as an upstream regulator of HSF1 protein expression; the ABL2 SH3 domain directly interacts with HSF1 at a noncanonical, proline-independent SH3 interaction motif. Allosteric (but not ATP-competitive) ABL2 inhibitors disrupt this interaction and impair HSF1 protein expression and HSF1-E2F transcriptional gene targets required for brain metastasis survival.\",\n      \"method\": \"Co-immunoprecipitation, SH3 domain binding assay, pharmacological inhibitor comparison (allosteric vs ATP-competitive), shRNA knockdown, transcriptional target measurement\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein interaction with domain specificity, pharmacological dissection with two inhibitor classes, and functional transcriptional readout; single lab\",\n      \"pmids\": [\"33318173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Abl2 acts as a regulator of endocytic vesicle maturation during HPV16 uptake; Abl2 inhibition causes accumulation of misshaped endocytic pits without reducing their number, whereas EGFR inhibition reduces pit number. Abl2 mediates downstream signaling of EGFR during HPV16 internalization, distinct from Src-mediated macropinocytosis.\",\n      \"method\": \"Pharmacological inhibition of Abl2 and EGFR, electron/fluorescence microscopy of endocytic pits, virus uptake quantification\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct morphological quantification of endocytic intermediates under Abl2 inhibition; single lab, two inhibitor classes compared\",\n      \"pmids\": [\"32188731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Arg/Abl2 depletion in endothelial cells activates both RhoA and Rac1, increases cell spreading, redistributes integrin-dependent adhesions to the cell periphery, improves ECM adhesion, and reduces barrier disruption in response to inflammatory agents. In vivo, genetic Arg deletion diminishes vascular leak in skin and lungs. Arg is activated in endothelium during inflammation in murine lungs and septic patient microvessels.\",\n      \"method\": \"siRNA depletion, RhoA/Rac1 activity assays, transendothelial electrical resistance, in vivo vascular permeability assays, immunofluorescence of patient tissue\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO in vivo plus siRNA depletion with multiple mechanistic readouts (GTPase activity, adhesion, barrier); single lab\",\n      \"pmids\": [\"33770321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Abl2 binding to cortactin tethers Abl2 in dendritic spines, where Abl2 and cortactin maintain a small pool of stable actin filaments required for spine stability. Disruption of Abl2:cortactin interactions by FRAP of GFP-actin eliminates the stable actin pool in spines and significantly reduces spine density. Tonic synaptic activity rescues spine loss after Abl2 depletion by promoting cortactin enrichment in spines.\",\n      \"method\": \"FRAP of GFP-actin in cultured hippocampal neurons, shRNA knockdown of Abl2, Abl2:cortactin interaction mutants, pharmacological synaptic activity manipulation\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — FRAP with multiple genetic and pharmacological manipulations, rescue experiments, and direct stable actin pool quantification; replicated mechanistic findings across related Koleske lab papers\",\n      \"pmids\": [\"33622779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Abl2 SH2 domain directly binds phosphotyrosine Y771 in the PDGFRβ cytoplasmic domain; PDGFRβ directly phosphorylates novel sites on Abl2 including Y116, Y139, Y161 (SH3 domain), Y299, Y303, Y310 (kinase domain); Y116, Y161, Y272, and Y310 are at/near the SH3/SH2-kinase linker interface. PDGFRβ-mediated phosphorylation activates Abl2 kinase activity, and mutation of Y116/Y161/Y272/Y310 to Phe abrogates this activation.\",\n      \"method\": \"In vitro direct binding assay, in vitro kinase assay with mass spectrometry phosphosite mapping, site-directed mutagenesis (4xF mutant), Abl2 kinase activity measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of receptor-kinase interaction and phosphorylation, MS-mapped sites, mutagenesis abolishing activation; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"34144039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TGFβ1/Smad signaling and reactive oxygen species production increase ubiquitination and degradation of Abl2 protein in ccRCC cells; Abl2 promotes TGFβ1-induced ccRCC cell invasion and invadopodium maturation as a downstream effector of TGFβ1 signaling.\",\n      \"method\": \"Primary ccRCC cell cultures, TGFβ1 treatment, ubiquitination assay, 3D invasion assay, matrix degradation assay, siRNA knockdown\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — ubiquitination assay and functional invasion readout in primary cells; single lab with two orthogonal mechanistic methods\",\n      \"pmids\": [\"36310399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Abl2 promotes microtubule nucleation by undergoing liquid-liquid phase separation (LLPS) and forming co-condensates with tubulin via its C-terminal half; Abl2 binds the MT lattice adjacent to damage sites, facilitates MT repair by recruiting fresh tubulin, and increases MT rescue frequency and lifetime. The Abl2Δ688-790 isoform retains MT-lattice binding but cannot bind tubulin, promote nucleation, or increase rescue. Cryo-EM supports engagement of tubulin C-terminal tails along an extended MT lattice conformation at damage sites. MT reassembly after nocodazole washout is severely impaired in Abl2 KO cells and rescued by Abl2 but not Abl2Δ688-790.\",\n      \"method\": \"In vitro MT dynamics reconstitution (TIRF), LLPS assay, cryo-EM, Abl2 KO COS-7 cells with nocodazole washout, domain deletion mutant rescue\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution, cryo-EM structure, LLPS assay, domain mutant analysis, and KO cell rescue; multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"37858340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The SH3 domain (exon 3) of Abl2 is essential for the efficacy of STAMP inhibitors (asciminib and TERN-701) targeting the Abl2 myristate pocket; different myristate pocket residues impact asciminib binding to Abl2 versus Abl1, predicting distinct resistance mutations in ABL2-rearranged ALL.\",\n      \"method\": \"Truncated ZC3HAV1::ABL2 isoforms, in vitro sensitivity assays, in silico molecular modeling, in vivo mouse model\",\n      \"journal\": \"Blood neoplasia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain truncation rescue experiments and in vivo model; computational modeling supporting structural interpretation; single lab\",\n      \"pmids\": [\"40678005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"FBXO31 directly interacts with ABL2 via its F-box motif and promotes ABL2 ubiquitination and proteasomal degradation, suppressing ABL2-driven TNBC cell proliferation, migration, invasion, and inhibition of xCT-mediated ferroptosis.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, overexpression/knockdown rescue experiments, ferroptosis assays, mouse xenograft\",\n      \"journal\": \"American journal of translational research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — co-IP of FBXO31-ABL2 interaction, ubiquitination assay, and functional rescue; single lab\",\n      \"pmids\": [\"42170439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"A chromosomal t(1;12)(q25;p13) translocation fuses ETV6 to ARG (ABL2), producing ETV6/ARG fusion transcripts that encode a protein containing the ETV6 PNT oligomerization domain and all functional ARG domains including the tyrosine kinase domain, identifying the first involvement of ARG in human leukemia.\",\n      \"method\": \"RT-PCR cloning of fusion transcripts, sequencing, characterization of open reading frame from AML-M3 cell line\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — RT-PCR identification and sequence characterization of fusion transcript; replicated in second cell line (PMID:12406085)\",\n      \"pmids\": [\"10706884\", \"12406085\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ABL2/Arg is a non-receptor tyrosine kinase that directly binds integrin β1 tails and receptor tyrosine kinases (PDGFRβ, EGFR, plexin A1) to become activated, whereupon it phosphorylates substrates including p190RhoGAP (inactivating RhoA to collapse the cytoskeleton), cortactin (stabilizing actin filaments and promoting Arp2/3-mediated branching), MNRR1/CHCHD2 (stimulating mitochondrial respiration), and HSF1 (driving a pro-metastatic transcriptional program); structurally, ABL2 uses its SH2, SH3, kinase, IWLEQ, and CH actin-binding domains to regulate actin filament dynamics, microtubule nucleation and repair via LLPS with tubulin, dendritic spine stability, and vascular barrier integrity, and is subject to ubiquitin-mediated degradation by FBXO31 and to activation by PDGFRβ phosphorylation at SH3/kinase linker residues.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ABL2/Arg is a non-receptor tyrosine kinase that couples cell-surface receptor signaling to remodeling of the actin and microtubule cytoskeletons, thereby controlling cell migration, dendritic spine and dendrite stability, and vascular barrier integrity [#0, #4, #18]. The kinase is switched on by direct engagement with upstream receptors: its SH2 domain binds the integrin \\u03b21 cytoplasmic tail (with reciprocal phosphorylation of \\u03b21 Tyr-783) and phosphotyrosine Y771 of PDGFR\\u03b2, the latter triggering phosphorylation of SH3/kinase-linker tyrosines (Y116, Y161, Y272, Y310) that activate Arg kinase activity [#7, #20]. Once active, Arg phosphorylates p190RhoGAP to inactivate RhoA and collapse the actin cytoskeleton downstream of the plexin A1/SEMA3F/NRP2 axis [#0], while a separate C-terminal module \\u2014 the (I/L)WEQ actin-binding and CH domains \\u2014 directly stabilizes actin filaments, drives Arp2/3-mediated branching, and cooperates with cortactin to maintain stable filament pools [#3, #6]. The same C-terminal half promotes microtubule nucleation and damage-site repair by forming liquid-liquid phase-separated co-condensates with tubulin [#22]. In neurons, Arg sustains dendrite arbor and dendritic spine stability through parallel RhoA-dependent and cortactin-tethering mechanisms, shaping synaptic maturation and plasticity [#4, #10, #19]. Beyond the cytoskeleton, Arg phosphorylates the mitochondrial protein MNRR1/CHCHD2 to stimulate respiration [#9], and drives pro-metastatic transcriptional programs by phosphorylating TAZ and stabilizing HSF1 [#14, #16]. Arg abundance is controlled by ubiquitin-mediated degradation, including by the F-box protein FBXO31 [#24]. A t(1;12) translocation fusing ETV6 to ABL2 implicates the kinase in human leukemia [#25], and structural studies define how ATP-competitive and allosteric/myristate-pocket inhibitors engage its catalytic domain [#1, #8, #23].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established the first link between ABL2/ARG and human malignancy by identifying a leukemia-associated fusion that retains the full ARG kinase.\",\n      \"evidence\": \"RT-PCR cloning and sequencing of ETV6/ARG fusion transcripts from an AML-M3 cell line\",\n      \"pmids\": [\"10706884\", \"12406085\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not test the transforming activity of the fusion protein\", \"Mechanism of ETV6 PNT-driven oligomerization/activation not demonstrated functionally\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Answered how ABL2 transduces guidance-receptor signals into cytoskeletal collapse, placing it downstream of plexin A1 and upstream of RhoA.\",\n      \"evidence\": \"Co-IP, siRNA, kinase-dead mutant, and RhoA GTP/GDP activity assays with in vitro phosphorylation of p190RhoGAP\",\n      \"pmids\": [\"18660502\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the structural basis of the plexin A1 interaction\", \"In vivo migratory consequences not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Provided atomic detail of the ABL2 catalytic domain bound to ATP-competitive and dual-site inhibitors, defining druggable conformations.\",\n      \"evidence\": \"X-ray co-crystal structures with imatinib, VX-680, and a triazole carbothioamide inhibitor\",\n      \"pmids\": [\"21417343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structures are of the isolated kinase domain, not full-length autoregulated protein\", \"No catalytic-cycle or activation-loop dynamics captured\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Clarified ABL2's paradoxical role in cancer, showing it promotes invasion/metastasis while suppressing primary tumor growth and Ras-MAPK signaling.\",\n      \"evidence\": \"shRNA knockdown in breast cancer xenografts with gene-expression, invasion, and intravasation readouts\",\n      \"pmids\": [\"22777352\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link between ABL2 and Ras-MAPK suppression not defined\", \"Direct substrates driving the invasion program not identified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified a non-catalytic mechanism by which ABL2 enhances cortactin-actin binding through its CH domain.\",\n      \"evidence\": \"Actin co-sedimentation with Arg deletion mutants and fragments\",\n      \"pmids\": [\"22849492\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro stoichiometry not linked to a cellular phenotype here\", \"Whether kinase activity modulates this binding untested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Dissected two distinct cytoskeletal pathways by which ABL2 stabilizes neuronal architecture \\u2014 RhoA-dependent dendrite stability versus cortactin-localization-dependent spine stability.\",\n      \"evidence\": \"shRNA, RhoA inhibition, NMDAR block, and cortactin-Arg actin-binding-domain fusion rescue in hippocampal neurons\",\n      \"pmids\": [\"23365224\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance addressed only in later work\", \"Upstream activator in neurons not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed that endogenous ABL2 isoforms differ in localization and substrate effects, including a nuclear isoform that phosphorylates CrkII.\",\n      \"evidence\": \"Isoform transfection in COS-7, immunofluorescence, and phospho-CrkII/p190RhoGAP western blots\",\n      \"pmids\": [\"23707396\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Overexpression may not reflect endogenous isoform stoichiometry\", \"Functional significance of nuclear CrkII phosphorylation unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Reconstituted ABL2's direct biochemical actions on actin, defining filament stabilization, Arp2/3 branch stimulation, CH-domain autoinhibition, and cofilin-severing potentiation.\",\n      \"evidence\": \"In vitro TIRF actin assembly, depolymerization, branching, and cofilin-severing assays with purified proteins and deletion mutants\",\n      \"pmids\": [\"25540195\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How kinase signaling toggles these activities in cells not shown\", \"Quantitative balance between branching and severing in vivo unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined the bipartite mechanism by which ABL2 directly binds and is activated by integrin \\u03b21, linking adhesion receptors to kinase activation.\",\n      \"evidence\": \"In vitro pulldowns, mutagenesis, kinase and binding assays, and cellular co-IP\",\n      \"pmids\": [\"25694433\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream substrates engaged specifically by integrin-activated ABL2 not mapped\", \"Structural model of the kinase-domain/\\u03b21-tail interface absent\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Captured the dasatinib-bound ARG catalytic domain, revealing a DFG-in conformation without activation-loop phosphorylation.\",\n      \"evidence\": \"2.5 \\u00c5 X-ray co-crystal structure of mouse ARG catalytic domain\",\n      \"pmids\": [\"25849507\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Isolated domain only; regulatory domains not present\", \"Implications for inhibitor selectivity over ABL1 not functionally tested here\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended ABL2 substrate scope into mitochondria, showing it phosphorylates MNRR1/CHCHD2 to promote COX binding and respiration, with disease-mutant validation.\",\n      \"evidence\": \"In vitro kinase assay, co-IP, fractionation, respiration measurement, and Q112H mutant analysis\",\n      \"pmids\": [\"27913209\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How ABL2 accesses the mitochondrial compartment not established\", \"Fraction of cellular respiration controlled by this axis unquantified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated in vivo that ABL2 is required for synaptic maturation, with its loss leaving immature GluN2B synapses and altered plasticity.\",\n      \"evidence\": \"Arg knockout mice with glutamate uncaging, electrophysiology, and spine morphometry\",\n      \"pmids\": [\"27335408\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular substrates linking ABL2 to GluN2B retention not identified\", \"Behavioral consequences not measured here\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected stress-hormone signaling to ABL2, showing corticosterone lowers ABL2 and substrate phosphorylation while pharmacological activation rescues dendrite and behavioral deficits.\",\n      \"evidence\": \"Western blots in cortisol-treated mice, DPH activator rescue, dendrite morphology, and behavioral tests\",\n      \"pmids\": [\"29107098\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which corticosterone reduces ABL2 protein not defined\", \"DPH specificity for ABL2 over ABL1 not fully controlled\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified ABL2 as a FLT3-interacting kinase that selectively dampens AKT signaling downstream of oncogenic FLT3-ITD.\",\n      \"evidence\": \"SH2 domain array, co-IP, and Ba/F3 overexpression with phospho-signaling readouts\",\n      \"pmids\": [\"28086240\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of selective AKT (not ERK/p38) suppression unresolved\", \"Endogenous ABL2 contribution versus overexpression untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Localized ABL2 to ventral actin waves and adhesion foci and showed its C-terminal half, not the kinase domain, drives this recruitment and lamellipodial control.\",\n      \"evidence\": \"TIRF live imaging, Abl2 KO cells, and N/C-terminal domain complementation\",\n      \"pmids\": [\"30256707\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding partner anchoring ABL2 to wave structures not pinpointed\", \"Role of kinase activity in wave dynamics separate from recruitment unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Placed ABL2 in a TAZ-driven feed-forward loop required for brain metastasis, with ABL2 phosphorylating TAZ to promote its nuclear localization.\",\n      \"evidence\": \"shRNA of ABL2/AXL/TAZ, in vivo brain metastasis model, TAZ phosphorylation, and BBB-penetrant ABL inhibitor\",\n      \"pmids\": [\"31825826\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"TAZ phosphosites targeted by ABL2 not mapped\", \"Generalizability beyond lung adenocarcinoma not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed ABL2 isoforms differentially program fibroblast activation and ECM remodeling, with distinct roles in adhesion versus invasion.\",\n      \"evidence\": \"Isoform rescue in Arg\\u2212/\\u2212 MEFs with proliferation, migration, focal-adhesion, and ECM contraction assays\",\n      \"pmids\": [\"30837227\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of isoform-specific outputs not defined\", \"In vivo fibroblast relevance untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined a non-catalytic ABL2 function in metastasis through direct SH3-domain binding and stabilization of HSF1, druggable by allosteric but not ATP-competitive inhibitors.\",\n      \"evidence\": \"Co-IP, SH3 binding assay, allosteric-vs-ATP-competitive inhibitor comparison, and transcriptional target measurement\",\n      \"pmids\": [\"33318173\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural detail of the noncanonical SH3-HSF1 interface absent\", \"How SH3 binding stabilizes HSF1 protein mechanistically unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Implicated ABL2 in endocytic vesicle maturation, acting downstream of EGFR to shape endocytic pits during HPV16 uptake.\",\n      \"evidence\": \"Pharmacological ABL2/EGFR inhibition with microscopy of endocytic pits and virus uptake quantification\",\n      \"pmids\": [\"32188731\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ABL2 substrates at endocytic sites not identified\", \"Reliance on inhibitor specificity without genetic confirmation\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Resolved how receptor tyrosine kinase signaling activates ABL2, mapping PDGFR\\u03b2 binding to the ABL2 SH2 domain and identifying linker phosphosites whose mutation abolishes activation.\",\n      \"evidence\": \"In vitro binding/kinase assays, MS phosphosite mapping, and 4xF mutagenesis\",\n      \"pmids\": [\"34144039\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural model of how linker phosphorylation relieves autoinhibition not solved\", \"Cellular substrates engaged after PDGFR\\u03b2 activation not profiled here\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established the molecular requirement for ABL2 in dendritic spine stability via a cortactin-tethered stable actin pool sustained by synaptic activity.\",\n      \"evidence\": \"GFP-actin FRAP, Abl2 shRNA, interaction mutants, and activity manipulation in hippocampal neurons\",\n      \"pmids\": [\"33622779\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How synaptic activity drives cortactin enrichment mechanistically unresolved\", \"Kinase activity requirement for stable pool maintenance not fully separated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined ABL2 as a regulator of endothelial barrier integrity, restraining cell spreading and adhesion through RhoA/Rac1 and contributing to inflammatory vascular leak.\",\n      \"evidence\": \"siRNA, RhoA/Rac1 activity assays, TEER, in vivo permeability assays, and patient microvessel staining\",\n      \"pmids\": [\"33770321\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream inflammatory signal activating endothelial ABL2 not identified\", \"Direct substrates mediating barrier disruption not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Positioned ABL2 as a degradation-controlled downstream effector of TGF\\u03b21 signaling driving invadopodium maturation in renal cancer.\",\n      \"evidence\": \"Primary ccRCC cultures, TGF\\u03b21 treatment, ubiquitination and 3D invasion/matrix-degradation assays\",\n      \"pmids\": [\"36310399\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase mediating TGF\\u03b21/ROS-induced ABL2 degradation not identified\", \"Direct invadopodial substrates of ABL2 unmapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed a kinase-independent ABL2 function in microtubule nucleation and repair via liquid-liquid phase separation with tubulin through its C-terminal half.\",\n      \"evidence\": \"In vitro MT dynamics reconstitution, LLPS assay, cryo-EM, and KO/domain-mutant rescue in cells\",\n      \"pmids\": [\"37858340\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Regulation of ABL2 condensate formation in cells not defined\", \"Crosstalk between MT and actin functions of the C-terminal half unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified FBXO31 as a direct E3-ligase regulator of ABL2 abundance, linking ABL2 degradation to suppression of TNBC growth and ferroptosis resistance.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, rescue experiments, ferroptosis assays, and xenografts\",\n      \"pmids\": [\"42170439\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Degron on ABL2 recognized by FBXO31 not mapped\", \"Whether this is the same axis as TGF\\u03b21-induced degradation untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showed the ABL2 SH3 domain and specific myristate-pocket residues govern STAMP/allosteric inhibitor efficacy and predict distinct resistance in ABL2-rearranged leukemia.\",\n      \"evidence\": \"Truncated ZC3HAV1::ABL2 isoforms, in vitro sensitivity, in silico modeling, and in vivo mouse model\",\n      \"pmids\": [\"40678005\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Predicted resistance mutations not yet clinically validated\", \"Structural basis of ABL2-vs-ABL1 myristate-pocket selectivity inferred computationally\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how ABL2's distinct outputs \\u2014 RhoA inactivation, direct actin/microtubule remodeling, mitochondrial and transcriptional substrate phosphorylation \\u2014 are selected and integrated by a single activated kinase in a given cellular context.\",\n      \"evidence\": \"No single study in the corpus reconstitutes substrate-selection logic across compartments\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model of context-dependent substrate selection\", \"Interplay between kinase-dependent and kinase-independent (LLPS, scaffolding) functions undefined\", \"Structural mechanism of full-length autoregulation unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 7, 9, 14, 20]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 7, 9, 20]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [3, 6, 13, 22]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [5, 13]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [6, 13, 22]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [7, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 7, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 14, 16, 25]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [4, 10, 19]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [14, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CTTN\", \"PDGFRB\", \"ITGB1\", \"PLXNA1\", \"CHCHD2\", \"HSF1\", \"FBXO31\", \"FLT3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}